Bet v 1‐specific IgE levels and PR‐10 reactivity discriminate silent sensitization from phenotypes of birch allergy

Elisyutina, O G; Феденко, Е С; Campana, Raffaela; Litovkina, Alla; Ilyina, Natalia; Kudlаy, D.А.; Egorenkov, Evgenii; Смирнов, В. В.; Valenta, Rudolf; Lupinek, Christian; Khaitov, Musa

doi:10.1111/all.13931

Cited by 22 publications

(25 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…97 It has also been reported that patients with high Bet v 1-specific IgE levels frequently suffer from oral allergy syndrome. 276 In addition, component combinations can define phenotypes with different clinical expression. It has recently been reported in an Italian cohort that sensitization to more than 5 nsLTPs out of the 8 present in ImmunoCAP ISAC is related to a higher incidence of food-induced systemic reactions, whereas sensitization to PR-10 or profilin pan-allergens is associated with milder symptoms.…”

Section: Interpretation Of Unexpected Resultsmentioning

confidence: 99%

A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

Ansotegui¹,

Melioli²,

Canonica³

et al. 2020

World Allergy Organization Journal

Self Cite

View full text Add to dashboard Cite

Precision allergy molecular diagnostic applications (PAMD@) is increasingly entering routine care. Currently, more than 130 allergenic molecules from more than 50 allergy sources are commercially available for in vitro specific immunoglobulin E (sIgE) testing. Since the last publication of this consensus document, a great deal of new information has become available regarding this topic, with over 100 publications in the last year alone. It thus seems quite reasonable to publish an update. It is imperative that clinicians and immunologists specifically trained in allergology keep abreast of the new and rapidly evolving evidence available for PAMD@. PAMD@ may initially appear complex to interpret; however, with increasing experience, the information gained provides relevant information for the allergist. This is especially true for food allergy, Hymenoptera allergy, and for the selection of allergen immunotherapy. Nevertheless, all sIgE tests, including PAMD@, should be evaluated within the framework of a patient's clinical history, because allergen sensitization does not necessarily imply clinical relevant allergies.

show abstract

Section: Interpretation Of Unexpected Resultsmentioning

confidence: 99%

A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

Ansotegui¹,

Melioli²,

Canonica³

et al. 2020

World Allergy Organization Journal

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, for many countries few important allergen sources can already be defined for prophylactic allergy vaccination. For example, birch pollen and cat allergies dominate in Scandinavia and Russia ( 17 , 20 , 83 ). A prophylactic birch pollen allergy vaccine would require only one allergen component, i.e., the major birch pollen allergen, Bet v 1 and a cat vaccine would be based primarily on the major cat allergen, Fel d 1.…”

Section: Unique Features Of Recombinant B Cell Epitope-based Peptide mentioning

confidence: 99%

“…Data obtained by longitudinal testing of children in population-based birth cohorts with micro-arrayed allergen molecules have shown that at the age of 4–6 years the majority of children have only clinically silent IgE sensitizations to respiratory allergens that later in life progress to symptoms of allergy ( 17 , 23 ). IgE levels associated with clinically silent IgE sensitization are usually low and it seems that threshold IgE levels for silent sensitization and symptomatic allergy can be defined ( 83 ). Furthermore, these studies have demonstrated that allergen-specific IgE reactivity patterns and levels measured early in life (i.e., at ages of 4–6 years) are useful to predict the progression toward symptoms of allergy ( 17 , 22 ).…”

Section: Unique Features Of Recombinant B Cell Epitope-based Peptide mentioning

confidence: 99%

Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible?

et al. 2020

Self Cite

View full text Add to dashboard Cite

Vaccines for infectious diseases have improved the life of the human species in a tremendous manner. The principle of vaccination is to establish de novo adaptive immune response consisting of antibody and T cell responses against pathogens which should defend the vaccinated person against future challenge with the culprit pathogen. The situation is completely different for immunoglobulin E (IgE)-associated allergy, an immunologically-mediated hypersensitivity which is already characterized by increased IgE antibody levels and T cell responses against per se innocuous antigens (i.e., allergens). Thus, allergic patients suffer from a deviated hyper-immunity against allergens leading to inflammation upon allergen contact. Paradoxically, vaccination with allergens, termed allergen-specific immunotherapy (AIT), induces a counter immune response based on the production of high levels of allergen-specific IgG antibodies and alterations of the adaptive cellular response, which reduce allergen-induced symptoms of allergic inflammation. AIT was even shown to prevent the progression of mild to severe forms of allergy. Consequently, AIT can be considered as a form of therapeutic vaccination. In this article we describe a strategy and possible road map for the use of an AIT approach for prophylactic vaccination against allergy which is based on new molecular allergy vaccines. This road map includes the use of AIT for secondary preventive vaccination to stop the progression of clinically silent allergic sensitization toward symptomatic allergy and ultimately the prevention of allergic sensitization by maternal vaccination and/or early primary preventive vaccination of children. Prophylactic allergy vaccination with molecular allergy vaccines may allow halting the allergy epidemics affecting almost 30% of the population as it has been achieved for vaccination against infectious diseases.

show abstract

“…Almost 30% of the population are affected by Immunoglobulin-E (IgE)-associated allergy, the most common hypersensitivity disease [1,2]. Allergic patients suffer from a variety of allergic symptoms such as rhinoconjunctivitis (i.e., hayfever), asthma, food allergy, allergic skin inflammation and life-threatening anaphylactic shock [3, 4, 5]. The longitudinal determination of the evolution of allergen-specific IgE responses and the development of allergic symptoms in population-based birth cohorts indicates that allergy often starts in the form of a clinically silent IgE sensitization in early childhood which later in life progresses to symptoms of increasing intensity [6, 7].…”

Section: Introductionmentioning

confidence: 99%

Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background: BM32, a grass pollen allergy vaccine containing four recombinant fusion proteins consisting of hepatitis B-derived PreS and hypoallergenic peptides from the major timothy grass pollen allergens adsorbed on aluminium hydroxide has been shown to be safe and to improve clinical symptoms of grass pollen allergy upon allergen-specific immunotherapy (AIT). We have investigated the immune responses in patients from a two years double-blind, placebo-controlled AIT field trial with BM32. Methods: Blood samples from patients treated with BM32 (n = 27) or placebo (Aluminium hydroxide) (n = 13) were obtained to study the effects of vaccination and natural allergen exposure on allergen-specific antibody, T cell and cytokine responses. Allergen-specific IgE, IgG, IgG 1 and IgG 4 levels were determined by Immuno-CAP and ELISA, respectively. Allergen-specific lymphocyte proliferation by 3 H thymidine incorporation and multiple cytokine responses with a human 17-plex cytokine assay were studied in cultured peripheral blood mononuclear cells (PBMCs). Findings: Two years AIT comprising two courses of 3 pre-seasonal injections of BM32 and a single booster after the first pollen season induced a continuously increasing (year 2 > year 1) allergen-specific IgG 4 response without boosting allergen-specific IgE responses. Specific IgG 4 responses were accompanied by low stimulation of allergen-specific PBMC responses. Increases of allergen-specific pro-inflammatory cytokine responses were absent. The rise of allergen-specific IgE induced by seasonal grass pollen exposure was partially blunted in BM32-treated patients. Interpretation: AIT with BM32 is characterised by the induction of a non-inflammatory, continuously increasing allergen-specific IgG 4 response (year 2 > year1) which may explain that clinical efficacy was higher in year 2 than in year 1. The good safety profile of BM32 may be explained by lack of IgE reactivity and low stimulation of allergen-specific T cell and cytokine responses. Fundings: Grants F4605, F4613 and DK 1248-B13 of the Austrian Science Fund (FWF).

show abstract

Bet v 1‐specific IgE levels and PR‐10 reactivity discriminate silent sensitization from phenotypes of birch allergy

Cited by 22 publications

References 10 publications

A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible?

Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response

Contact Info

Product

Resources

About